- Accent Microcell makes the invisible ingredients that hold pills together and make them work - it is a manufacturer of pharmaceutical excipients, the binders, disintegrants and stabilisers that turn active drugs into tablets and capsules. The business began as a modest partnership in 2001, pivoted early to exports in 2008, and has since grown into a supplier to over 75 countries from two Gujarat plants. Everything it does follows a “volume-value” logic: it anchors itself in high-volume production of Microcrystalline Cellulose (MCC), the workhorse excipient, while steadily expanding into premium, higher-margin specialty excipients that its existing customers already need.
Business segments
A single engine powering two value tiers - a high-volume MCC core that generates the cash and customer relationships, and a premium-excipients expansion layered on top to raise margins and deepen the moat.
1. Cellulose-based excipients: the workhorse ingredients behind every tablet
The company makes and sells the inactive powders that give pills their shape, strength and release profile - MCC alone comes in 22 grades, and the broader portfolio spans over 15 products sold under four brands to pharmaceutical, nutraceutical and food manufacturers worldwide.
- The anchor product is everywhere - Microcrystalline Cellulose (MCC) is a purified wood-pulp derivative that acts as a binder, diluent and disintegrant in tablets, and the company produces it in particle sizes from 20 to 180 microns so customers can dial in exactly the compressibility and flow they need. It is the raw material that formulators buy to make finished medicines, supplements and even food products.
- A full toolkit, not just one powder - beyond plain MCC, the portfolio includes Silicified MCC (MCC fused with Colloidal Silicon Dioxide for better flow), MCC Spheres (tiny carrier beads for controlled drug release), and a co-processed MCC-CMC blend that binds harder and disintegrates faster. There are also super-disintegrants like Croscarmellose Sodium (CCS) and Sodium Starch Glycolate (SSG) that swell on contact with water to break a tablet apart, plus Magnesium Stearate as a lubricant and Powdered Cellulose as a filler.
- Two plants, two drying technologies - Unit I at Pirana (2,000 tonnes per year, running full) uses spin-flash drying for non-spray-dried MCC and serves the domestic market, while Unit II at the Dahej SEZ (7,200 tonnes per year, running at 95%) uses spray drying to make the premium “ACCEL” brand MCC that commands better pricing for its superior tableting properties. Together they give the company over 9,200 tonnes of annual capacity.
- Quality paperwork is the entry ticket - the company holds EXCiPACT, GMP, ISO 9001, FSSC 22000, HACCP, Kosher and Halal certifications, and its Dahej unit has a US-DMF filing, which is the regulatory door-key for selling excipients into the American pharmaceutical supply chain.
2. Premium excipients at Unit III: moving up the value chain
A new greenfield plant in Kheda is being built to manufacture CCS, CMC and SSG - specialty excipients that fetch higher margins and are already demanded by the company’s export customers, with Phase One alone expected to add ₹150-160 crore in peak revenue.
- Making what it used to buy - the company currently procures Carboxymethylcellulose (CMC) as a raw material to produce Croscarmellose Sodium (CCS) in-house, so bringing CMC production under its own roof at Unit III is a backward-integration move that cuts out a supplier. The new plant will also make Sodium Starch Glycolate (SSG), completing a trio of premium disintegrants.
- Customers are already waiting - the company has a set of buyers lined up for CCS, with 80-90% of them being export clients, a mix of new accounts and existing relationships that already buy MCC from the company. Domestic production from Unit III began in May 2025, though the ethanol-based CCS process requires 20-25 days of trial runs before commercial output stabilises.
- Phased capacity, deliberate ramp - Phase One carries a ₹70 crore capital outlay and is designed to go from 45-50% utilisation in year one to 70% in year two, reaching full capacity by FY 2028. Phase Two is expected to contribute another ₹220-250 crore in annual revenue once fully commissioned, lifting total company capacity from 9,200 to 12,000 tonnes per year.
- A hedge wrapped in a growth plan - the expansion is explicitly aimed at shifting the product mix from commodity excipients toward specialties, targeting 30-40% of output for the domestic market, which also diversifies the customer base away from pure export dependence and insulates against geopolitical and tariff risks.
Group structure and partners
A standalone, promoter-led company with no subsidiaries - a single entity listed on the NSE SME platform, run by its four first-generation founders.
- The company has no subsidiaries, joint ventures or equity stakes in other businesses; it reports its two manufacturing units - Dahej SEZ and Pirana - as separate geographical segments for accounting purposes.
- Leadership sits with the four founding promoters: Mr. Vasant Vadilal Patel (Chairman), Mr. Ghanshyam Arjanbhai Patel (Managing Director & CFO), Mr. Nitin Jasvantbhai Patel (Executive Director overseeing R&D and technical operations), and Mr. Vinodbhai Manibhai Patel (Executive Director running the Pirana unit and CSR).
- The company listed on the NSE SME Emerge platform in December 2023, with its IPO oversubscribed more than 362 times, and holds a credit rating of Care BBB+ (Stable) for long-term bank facilities and Care A2 for short-term facilities.
- In October 2024, the board approved a rights issue to raise up to ₹40 crore from eligible shareholders, with a committee constituted to decide the terms.